Dublin, Ireland, June 24, 2025 (GLOBE NEWSWIRE) -- Brera Holdings PLC ("Brera Holdings" or the "Company") (Nasdaq: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men's and women's sports clubs through a multi-club ownership ("MCO") strategy, today announced a 1-for-10 reverse share split (the "Reverse Share Split") of the Company's ordinary shares, wherein the 50,000,000 Class A Ordinary Shares of nominal value $0.005 each will be consolidated on a 1-for-1 ...

SmartGateway Deployment Addresses California’s New Mandate for Hospital Weapons DetectionTORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its SmartGateway has been selected by San Mateo Medical Center, located in San Mateo, CA, to strengthen the facility’s security and provide AI-powered weapon detection. Xtract One’s leading technology-driven threat detection and security solutions are designed to enhance ...

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer- acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: ...

Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Approximately 16 subjects will be enrolled in the IOLITE study. The sample size was calculated based on the average symptomatic days per month and standard deviation data from subjects enrolled in the natural history study who would be otherwise eligible for IOLITE and provides 90% power to detect an effect size of at least 25%, allowing for a dropout rate up to 20%. Enrolled patients will initially receive either a sin ...

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to ...

Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) ("Enzo" or the "Company") today announced that on June 23, 2025, following the market close, it entered into an Agreement and Plan of Merger (the "Merger Agreement") to be acquired by Battery Ventures, a global, technology-focused investment firm, through its newly formed entity Bethpage Parent, In ...

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that it has completed the U.S. Food and Drug Administration's (FDA) Plant Biotechnology Consultation Program for its altered lignin alfalfa trait with the FDA notifying Cibus that it has no further questions concerning the use of altered lignin alfalfa in food or feed. This press release contains "forward ...

Ken Lapierre, President and Chief Executive Officer, commented, "We are delighted to kick-start the summer field season at Gold Anchor. The program will include detailed till sampling, prospecting, geological and geophysical work at its Lane Pond Gold Target and other high-priority gold targets in the vicinity. At Lane Pond, significant gold values have been found in recent and historical sampling in an area 6,000 metres long and located proximal to the Appleton Fault. The Appleton Fault is the most prolifi ...

REDWOOD CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has partnered with Royalty Pharma on $2 billion in flexible funding to support Revolution Medicines' independent global development and commercialization strategy and operations. Revolution Medicines retains full strategic and executional control of product development and commer ...

文章核心观点 - 蒂雷医疗（Tilray Medical）宣布在意大利推出三种新的医用大麻花卉品种，标志其欧洲扩张取得重要里程碑，成为意大利首家获卫生部授权进口和分销自有品牌医用大麻花卉的公司 [1] 公司动态 - 本月起蒂雷医疗的Tilray THC 25%、Tilray THC 18%、Tilray THC 9% / CBD 9%三款产品获意大利治疗用途批准，并可通过意大利各地药房分销 [2][7] - 蒂雷医疗首席战略官兼国际业务主管表示这一里程碑凸显医用大麻对有需要患者的重要治疗作用，公司自豪能在意大利扩展医用大麻产品组合，并感谢卫生部信任和提供监管框架 [2] 公司业务布局 - 蒂雷医疗在德国、意大利、葡萄牙、波兰和英国开展业务，继续引领欧洲医用大麻市场，提供广泛的欧盟GMP认证医用大麻产品 [2] 公司介绍 - 蒂雷医疗致力于通过安全可靠地提供全球医用大麻品牌组合，改变有需要患者的生活并维护其尊严，旗下品牌包括Tilray Medical、Broken Coast等 [3] - 蒂雷医疗从加拿大首批获批的医用大麻许可生产商发展为在葡萄牙和德国建立首个欧盟GMP认证大麻生产设施的公司，如今是领先的医用大麻供应商 [3] 母公司介绍 - 蒂雷品牌公司是全球领先的生活方式和消费品包装公司，业务覆盖加拿大、美国、欧洲、澳大利亚、新西兰和拉丁美洲，在大麻、饮料、健康和娱乐领域发挥变革力量 [5] - 蒂雷品牌公司的使命是成为领先的高端生活方式公司，旗下拥有40多个品牌，业务遍及20多个国家，提供全面的大麻产品、大麻基食品和精酿饮料 [5] 信息获取渠道 - 如需蒂雷医疗更多信息，可访问Tilray Medical Europe、Tilray Medical Canada和Tilray Medical Australia - New Zealand [4] - 如需了解蒂雷品牌公司如何通过连接时刻提升生活品质，可访问Tilray.com并在所有社交平台关注@Tilray [6] - 媒体咨询可联系news@tilray.com，投资者关系咨询可联系investors@tilray.com [9]